- Home
- IAUX vs CMPX Comparison
IAUX vs CMPX Comparison
Compare IAUX & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- CMPX
- Stock Information
- Founded
- IAUX 2020
- CMPX 2014
- Country
- IAUX United States
- CMPX United States
- Employees
- IAUX N/A
- CMPX N/A
- Industry
- IAUX
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- CMPX Health Care
- Exchange
- IAUX Nasdaq
- CMPX Nasdaq
- Market Cap
- IAUX 253.2M
- CMPX 291.8M
- IPO Year
- IAUX N/A
- CMPX N/A
- Fundamental
- Price
- IAUX $0.70
- CMPX $2.37
- Analyst Decision
- IAUX Buy
- CMPX Strong Buy
- Analyst Count
- IAUX 1
- CMPX 8
- Target Price
- IAUX $1.50
- CMPX $13.13
- AVG Volume (30 Days)
- IAUX 11.9M
- CMPX 801.4K
- Earning Date
- IAUX 08-11-2025
- CMPX 08-11-2025
- Dividend Yield
- IAUX N/A
- CMPX N/A
- EPS Growth
- IAUX N/A
- CMPX N/A
- EPS
- IAUX N/A
- CMPX N/A
- Revenue
- IAUX $55,970,000.00
- CMPX $850,000.00
- Revenue This Year
- IAUX $108.70
- CMPX N/A
- Revenue Next Year
- IAUX $60.68
- CMPX N/A
- P/E Ratio
- IAUX N/A
- CMPX N/A
- Revenue Growth
- IAUX N/A
- CMPX N/A
- 52 Week Low
- IAUX $0.34
- CMPX $0.77
- 52 Week High
- IAUX $1.26
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- IAUX 67.93
- CMPX 53.99
- Support Level
- IAUX $0.61
- CMPX $2.17
- Resistance Level
- IAUX $0.73
- CMPX $2.49
- Average True Range (ATR)
- IAUX 0.04
- CMPX 0.18
- MACD
- IAUX 0.01
- CMPX -0.01
- Stochastic Oscillator
- IAUX 87.28
- CMPX 34.85
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.